Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4,088 | 4,139 | 4,452 | 4,656 | 4,373 | 4,253 | 4,090 | 3,992 |
| Operating profit | $m | 343 | 166 | ||||||
| Net profit | $m | -163 | -69 | -141 | -13 | -172 | -1,425 | -1,770 | - |
| EPS reported | $ | -10.29 | -12.77 | ||||||
| Operating cashflow per share | $ | 1.72 | 2.13 | ||||||
| Capex per share | $ | 0.67 | 0.52 | ||||||
| FCF per share | $ | 1.05 | 1.61 | ||||||
| Free cash flow | $m | 145 | 224 | ||||||
| Net debt | $m | 3,274 | 2,846 | ||||||
| Book value equity | $m | 2,936 | 2,440 | ||||||
| Book value per share | $ | 21.19 | 17.51 | ||||||
| Number of shares | m | 138.5 | 139.4 | ||||||
| DPS (TTM paid) | $ | 1.16 | 1.16 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.66 | 0.94 | ||||||
| P/S LTM | x | 0.45 | 0.56 | ||||||
| P/FCF LTM | x | 13.29 | 10.26 | ||||||
| EV/EBITDA LTM | x | -6.72 | -4.65 | ||||||
| EV/Sales LTM | x | 1.26 | 1.26 | ||||||
| Earnings Yield LTM | % | -73.93% | -75.43% | ||||||
| FCF Yield | % | 7.53% | 9.75% | ||||||
| Quality | |||||||||
| ROE | % | -48.56% | -68.13% | ||||||
| ROIC | % | 4.53% | 2.56% | ||||||
| Operating margin | % | 8.07% | 4.05% | ||||||
| Gross margin | % | 35.14% | 32.33% | ||||||
| FCF/Sales | % | 3.41% | 5.47% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -2.75% | -4.47% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -40.68% | -17.50% | ||||||
| Operating Profit Growth | % | +204.07% | -40.70% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 8.26% | 7.01% | ||||||
| Dividend Growth | % | +5.07% | +1.22% | ||||||
| Payout Ratio | % | -11.18% | -11.27% | ||||||
| FCF/Debt | x | 0.04 | 0.07 | ||||||
| Net Debt/EBITDA | x | -4.31 | -2.57 | ||||||
| EBIT/Net interest | x | 2.11 | 1.13 | ||||||
| Net debt/market cap | % | 169.84% | 123.90% | ||||||
| Net debt/Equity | x | 1.12 | 1.17 | ||||||
| Gross debt/equity | x | 1.35 | 1.35 | ||||||
ETFs that hold Perrigo
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco High Yield Equity Dividend Achievers ETF | PEY | 2 | 3.71% |
| Global X - SuperDividend ETF | SDIV | 7 | 1.64% |
| Global X Superdividend UCITS ETF USD | UDIV.DE | 7 | 1.64% |
| Global X - SuperDividend U.S. ETF | DIV | 10 | 2.26% |
| Federated Hermes MDT Small Cap Core ETF | FSCC | 8 | 1.08% |
Funds with Perrigo among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Similar companies
- Shandong Buchang Pharmaceuticals Co., Ltd.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- China Resources Double-Crane Pharmaceutical Co.,Ltd.
- Alembic Pharmaceuticals Limited
- China Resources Jiangzhong Pharmaceutical Co.,Ltd
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd
- Harbin Pharmaceutical Group Co., Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco High Yield Equity Dividend Achievers ETF | PEY | 2 | 3.71% |
| Global X - SuperDividend ETF | SDIV | 7 | 1.64% |
| Global X Superdividend UCITS ETF USD | UDIV.DE | 7 | 1.64% |
| Global X - SuperDividend U.S. ETF | DIV | 10 | 2.26% |
| Federated Hermes MDT Small Cap Core ETF | FSCC | 8 | 1.08% |
Funds with Perrigo among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- Shandong Buchang Pharmaceuticals Co., Ltd.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- China Resources Double-Crane Pharmaceutical Co.,Ltd.
- Alembic Pharmaceuticals Limited
- China Resources Jiangzhong Pharmaceutical Co.,Ltd
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd
- Harbin Pharmaceutical Group Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free